研究者
J-GLOBAL ID：202201011804873913   更新日: 2023年05月29日

中山 秀樹

ナカヤマ ヒデキ | Nakayama Hideki
所属機関・部署：
独立行政法人国立病院機構 九州がんセンター 小児・思春期腫瘍科

独立行政法人国立病院機構 九州がんセンター 小児・思春期腫瘍科 について


職名： 医長
論文 (47件)：
  • Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu, Hiroyuki Fujisaki, Yoshiyuki Kosaka, Hiroya Hashimoto, Akiko M Saito, Keizo Horibe. Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). International journal of hematology. 2023. 117. 5. 786-786
  • Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu, Hiroyuki Fujisaki, Yoshiyuki Kosaka, Hiroya Hashimoto, Akiko M Saito, Keizo Horibe. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). International journal of hematology. 2022. 116. 4. 612-621
  • Takashi Taga, Shiro Tanaka, Daisuke Hasegawa, Kiminori Terui, Tsutomu Toki, Shotaro Iwamoto, Hidefumi Hiramatsu, Takako Miyamura, Yoshiko Hashii, Hiroshi Moritake, et al. Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia. 2021. 35. 12. 3622-3624
  • Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu, Hiroyuki Fujisaki, Yoshiyuki Kosaka, Hiroya Hashimoto, Akiko Saito, Keizo Horibe. Phase I Study of Inotuzumab Ozogamicin in Children with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia in Japan (Ino-Ped-All-1). PEDIATRIC BLOOD & CANCER. 2021. 68
  • Takashi Taga, Shiro Tanaka, Daisuke Hasegawa, Kiminori Terui, Tsutomu Toki, Shotaro Iwamoto, Hidefumi Hiramatsu, Takako Miyamura, Yoshiko Hashii, Hiroshi Moritake, et al. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia. 2021. 35. 9. 2508-2516
もっと見る
MISC (6件)：
  • Takahiro Aoki, Hiroyuki Takahashi, Shiro Tanaka, Norio Shiba, Daiichiro Hasegawa, Shotaro Iwamoto, Kiminori Terui, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, et al. Predisposition to Prolonged Neutropenia After Chemotherapy was Associated With Better Prognosis in Patients With Acute Myeloid Leukemia. PEDIATRIC BLOOD & CANCER. 2019. 66. S21-S21
  • Takako Miyamura, Shiro Tanaka, Hideki Nakayama, Hiroshi Moritake, Daisuke Tomizawa, Akiko M. Saito, Akio Tawa, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, et al. Clinical and Biological Features of Pediatric Acute Myeloid Leukemia with Primary Induction Failure in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Study. BLOOD. 2016. 128. 22
  • Hidemasa Matsuo, Naomi Nakamura, Daisuke Tomizawa, Akiko M. Saito, Nobutaka Kiyokawa, Keizo Horibe, Yoko Nishinaka-Arai, Mayu Tokumasu, Hiroshi Itoh, Yasuhiko Kamikubo, et al. Prognostic Significance of CXCR4 Overexpression in Pediatric Acute Myeloid Leukemia with Low-Risk: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group. BLOOD. 2015. 126. 23
  • Hiroshi Moritake, Shiro Tanaka, Hideki Nakayama, Takako Miyamura, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, Akiko M. Saito, Norio Shiba, Yasuhide Hayashi, et al. The Outcome of Relapsed Childhood Core Binding Factor Acute Myeloid Leukemia: A Report from the JPLSG AML-05R Study. BLOOD. 2015. 126. 23
  • Hidemasa Matsuo, Mio Kajihara, Daisuke Tomizawa, Tomoyuki Watanabe, Akiko Moriya Saito, Junichiro Fujimoto, Keizo Horibe, Mayu Tokumasu, Hiroshi Itoh, Hideki Nakayama, et al. Double CEBPA Mutations Are Not Associated With Favorable Clinical Outcome In Pediatric AML: A Report From The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). BLOOD. 2013. 122. 21
もっと見る
※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る

TOP

BOTTOM